Chalid Assaf, MD, PhD, Helios Klinikum Krefeld, Krefeld, Germany, discusses the latest updates in the treatment of cutaneous T-cell lymphoma (CTCL), in particular highlighting the use of brentuximab vedotin in patients with late-stage disease, and questioning the importance of CD30 positivity in its use. Dr Assaf reports that CTCL tumor samples expressing below 10% of CD30 were found to have very good responses to brentuximab vedotin. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.